These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25628399)

  • 1. An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma.
    von Tresckow B; Morschhauser F; Ribrag V; Topp MS; Chien C; Seetharam S; Aquino R; Kotoulek S; de Boer CJ; Engert A
    Clin Cancer Res; 2015 Apr; 21(8):1843-50. PubMed ID: 25628399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
    Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
    Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CSF-1-receptor inhibitor, JNJ-40346527 (PRV-6527), reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis.
    Manthey CL; Moore BA; Chen Y; Loza MJ; Yao X; Liu H; Belkowski SM; Raymond-Parks H; Dunford PJ; Leon F; Towne JE; Plevy SE
    PLoS One; 2019; 14(11):e0223918. PubMed ID: 31710624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
    Shah JJ; Jakubowiak AJ; O'Connor OA; Orlowski RZ; Harvey RD; Smith MR; Lebovic D; Diefenbach C; Kelly K; Hua Z; Berger AJ; Mulligan G; Faessel HM; Tirrell S; Dezube BJ; Lonial S
    Clin Cancer Res; 2016 Jan; 22(1):34-43. PubMed ID: 26561559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
    Batlevi CL; Kasamon Y; Bociek RG; Lee P; Gore L; Copeland A; Sorensen R; Ordentlich P; Cruickshank S; Kunkel L; Buglio D; Hernandez-Ilizaliturri F; Younes A
    Haematologica; 2016 Aug; 101(8):968-75. PubMed ID: 27151994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
    Dowlati A; Harvey RD; Carvajal RD; Hamid O; Klempner SJ; Kauh JSW; Peterson DA; Yu D; Chapman SC; Szpurka AM; Carlsen M; Quinlan T; Wesolowski R
    Invest New Drugs; 2021 Aug; 39(4):1057-1071. PubMed ID: 33624233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
    Manthey CL; Johnson DL; Illig CR; Tuman RW; Zhou Z; Baker JF; Chaikin MA; Donatelli RR; Franks CF; Zeng L; Crysler C; Chen Y; Yurkow EJ; Boczon L; Meegalla SK; Wilson KJ; Wall MJ; Chen J; Ballentine SK; Ott H; Baumann C; Lawrence D; Tomczuk BE; Molloy CJ
    Mol Cancer Ther; 2009 Nov; 8(11):3151-61. PubMed ID: 19887542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
    Nishina T; Takahashi S; Iwasawa R; Noguchi H; Aoki M; Doi T
    Invest New Drugs; 2018 Jun; 36(3):424-434. PubMed ID: 28965185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.
    Northfelt DW; Ramanathan RK; Cohen PA; Von Hoff DD; Weiss GJ; Dietsch GN; Manjarrez KL; Randall TD; Hershberg RM
    Clin Cancer Res; 2014 Jul; 20(14):3683-91. PubMed ID: 24807889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
    Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
    Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
    Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
    Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
    Ghobrial IM; Siegel DS; Vij R; Berdeja JG; Richardson PG; Neuwirth R; Patel CG; Zohren F; Wolf JL
    Am J Hematol; 2016 Jun; 91(4):400-5. PubMed ID: 26800393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma.
    Song Y; Wu J; Chen X; Lin T; Cao J; Liu Y; Zhao Y; Jin J; Huang H; Hu J; Luo J; Zhang L; Xue H; Zhang Q; Wang W; Chen C; Feng J; Zhu J
    Clin Cancer Res; 2019 Dec; 25(24):7363-7369. PubMed ID: 31420358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
    Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
    Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation.
    Scheid C; Reece D; Beksac M; Spencer A; Callander N; Sonneveld P; Kalimi G; Cai C; Shi M; Scott JW; Stewart AK
    Eur J Haematol; 2015 Oct; 95(4):316-24. PubMed ID: 25402977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
    Munster PN; Britten CD; Mita M; Gelmon K; Minton SE; Moulder S; Slamon DJ; Guo F; Letrent SP; Denis L; Tolcher AW
    Clin Cancer Res; 2007 Feb; 13(4):1238-45. PubMed ID: 17317835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of sorafenib in patients with relapsed or refractory lymphoma.
    Guidetti A; Carlo-Stella C; Locatelli SL; Malorni W; Pierdominici M; Barbati C; Mortarini R; Devizzi L; Matteucci P; Marchianò A; Lanocita R; Farina L; Dodero A; Tarella C; Di Nicola M; Corradini P; Anichini A; Gianni AM
    Br J Haematol; 2012 Jul; 158(1):108-19. PubMed ID: 22571717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.
    Younes A; Sureda A; Ben-Yehuda D; Zinzani PL; Ong TC; Prince HM; Harrison SJ; Kirschbaum M; Johnston P; Gallagher J; Le Corre C; Shen A; Engert A
    J Clin Oncol; 2012 Jun; 30(18):2197-203. PubMed ID: 22547596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.